
Active Biotech: Nya data från fas 2-studien LEGATO-HD med laquinimod i Huntingtons sjukdom presenteras på den internationella kongressen ”Parkinson’s disease and movement disorders”
Lund den 23 september, 2019 - Active Biotech (NASDAQ STOCKHOLM: ACTI) meddelar att nya data från fas 2-studien LEGATO-HD med laquinimod i Huntingtons sjukdom kommer att presenteras i Nice, Frankrike, på den internationella kongressen Parkinson’s disease and Movement disorders 22-26 september, 2019. Resultaten kommer att presenteras i tre postrar.
Abstrakt och postrar kommer att finnas tillgängliga på Active Biotech hemsida (www.activebiotech.com) i anslutning till presentationen.
P24 -
Magnetic Resonance Spectroscopy Evaluation of Neuronal Integrity and Astrocytosis in a Phase 2 study of Laquinimod as a Treatment for Huntington Disease (LEGATO-HD)
Blair R. Leavitt1, Ralf Reilmann2, Mark Forrest Gordon3, Karen E. Anderson4, Andrew Feigin5, Sarah J. Tabrizi6, Julie C. Stout7, Paola Piccini8, Bretta Russell-Schulz1, Alex L. Mackay1, Beth Borowsky3,
Gail Rynkowski3, Rita Volkinshtein3, Juha-Matti Savola3, Michael R. Hayden3
1University of British Columbia, 2George-Huntington-Institute, 3Teva Pharmaceuticals, 4MedStar Georgetown University Hospital & Georgetown University Medical Center, 5NYU Langone Health, 6UCL Institute of Neurology, 7Monash University, 8Imperial College Hayden3
P43 - Brain MRI Volume Changes after 12 months laquinimod treatment of Huntington disease (LEGATO-HD)
Ralf Reilmann1, Mark Forrest Gordon2, Karen E. Anderson3, Andrew Feigin4, Sarah J. Tabrizi5, Blair R. Leavitt6, Julie C. Stout7, Paola Piccini8, Nicola Hobbs9, Richard Manber9, Beth Borowsky2, Gail Rynkowski2, Rita Volkinshtein2, Juha-Matti Savola2 and Michael Hayden2
1George-Huntington-Institute, 2Teva Pharmaceuticals, 3MedStar Georgetown University Hospital & Georgetown University Medical Center, 4NYU Langone Health, 5UCL Institute of Neurology, 6University of British Columbia, 7Monash University, 8Imperial College, 9IXICO plc, London
P44 - Quantitative Motor (Q-Motor) Assessments Suggest a Beneficial Central Effect of Laquinimod in a Phase II Study in Huntington Disease (LEGATO-HD)
Ralf Reilmann1, Mark Forrest Gordon2, Robin Schubert1, Karen E. Anderson3, Andrew Feigin4, Sarah J. Tabrizi5, Blair R. Leavitt6, Julie C. Stout7, Paola Piccini8, Beth Borowsky2, Gail Rynkowski2,
Rita Volkinshtein2, Juha-Matti Savola2, Michael R. Hayden2
1George-Huntington-Institute, 2Teva Pharmaceuticals, 3MedStar Georgetown University Hospital & Georgetown University Medical Center, 4NYU Langone Health, 5University College of London, 6University of British Columbia, 7Monash University, 8Imperial College London
OM LEGATO-HD
LEGATO-HD är en multinationell, multicenter, randomiserad, dubbelblind, placebokontrollerad, parallellgrupp, fas 2-studie av laquinimod som potentiell behandling av patienter med Huntingtons sjukdom. Studien utformades för att utvärdera tre doser (0,5 mg, 1,0 mg och 1,5 mg dagligen) jämfört med placebo. Den högsta dosen, 1.5 mg avbröts i januari 2016, som en försiktighetsåtgärd efter att kardiovaskulära säkerhetsproblem observerats i multipel skleros-studier med laquinimod på 1,2 mg respektive 1,5 mg. Inga liknande problem identifierades i LEGATO-HD studien.
Det primära studiemålet, att utvärdera förändring efter 12 månaders behandling jämfört med studiestart i UHDRS-TMS, för dosen 1,0 mg jämfört med placebo uppnåddes inte. Däremot uppnåddes det sekundära målet procentuell förändring av hjärnatrofi (caudatusvolym) efter 12 månader jämfört med studiestart för dosen 1,0 mg jämfört med placebo. Säkerhetsprofilen i studien var likvärdig med den förväntade i patientpopulationen.
I de explorativa utfallen ingår förändring av Unified Huntington's Disease Rating Scale - Total Motor Score (UHDRS-TMS) och procentuell förändring i hjärnatrofi för dosen 0,5 mg, samt förändringar i uppmätt motorisk funktion (Q-motor), kognitiv funktion, funktionskapacitet, neuronal integritet och astrocytos (MRS) såväl som hjärnvolymer för doserna 1,0 respektive 0,5 mg var för sig. Säkerhetsmåtten omfattade rapporterade biverkningar, kliniska laboratorietester, vitalparametrar, EKGs, fysiska undersökningar och självmordsbenägenhet.
Studien genomfördes av Teva i samarbete med Huntington Study Group och European Huntington's Disease Network. Studien är registrerad som NCT02215616 på clinicaltrials.gov och dess EudraCT-nummer är 2014-000418-75.
Lund den 23 september, 2019
Active Biotech AB (publ)
För ytterligare information, vänligen kontakta:
Helén Tuvesson, VD
Tel +46 46 19 20 95
Hans Kolam, CFO
Tel +46 46 19 20 44
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) är ett bioteknikföretag fokuserat på utveckling av läkemedel för behandling av neurodegenerativa/inflammatoriska sjukdomar och cancer. Laquinimod, en substans i tablettform med unika immunmodulerande egenskaper utvecklas för neurodegenerativa sjukdomar. ANYARA (naptumumab), en immunterapi, befinner sig i utveckling för behandling av cancer i samarbete med NeoTX Therapeutics Ltd. Vidare bedrivs kommersiella aktiviteter för projekten tasquinimod, paquinimod och SILC. För ytterligare information besök www.activebiotech.com.
Active Biotech AB
(org.nr 556223-9227)
Box 724, 220 07 Lund
Tfn 046 19 20 00
Denna information är sådan information som Active Biotech AB är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 23 september, 2019, kl. 08.30.
Bilaga
För att se det här innehållet från www.globenewswire.com måste du ge ditt medgivande sidans topp.Om
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Följ GlobeNewswire by notified
Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.
Senaste pressmeddelandena från GlobeNewswire by notified
Iveco Group signs a 150 million euro term loan facility with Cassa Depositi e Prestiti to support investments in research, development and innovation11.6.2024 12:00:00 CEST | Press release
Turin, 11th June 2024. Iveco Group N.V. (EXM: IVG), a global automotive leader active in the Commercial & Specialty Vehicles, Powertrain and related Financial Services arenas, has successfully signed a term loan facility of 150 million euros with Cassa Depositi e Prestiti (CDP), for the creation of new projects in Italy dedicated to research, development and innovation. In detail, through the resources made available by CDP, Iveco Group will develop innovative technologies and architectures in the field of electric propulsion and further develop solutions for autonomous driving, digitalisation and vehicle connectivity aimed at increasing efficiency, safety, driving comfort and productivity. The financed investments, which will have a 5-year amortising profile, will be made by Iveco Group in Italy by the end of 2025. Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a
DSV, 1115 - SHARE BUYBACK IN DSV A/S11.6.2024 11:22:17 CEST | Press release
Company Announcement No. 1115 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-25478,1001,023.01489,100,86026:3 June 20247,0001,050.597,354,13027:4 June 20245,0001,055.705,278,50028:6 June20243,0001,096.273,288,81029:7 June 20244,0001,106.174,424,68
Landsbankinn hf.: Offering of covered bonds11.6.2024 11:16:36 CEST | Press release
Landsbankinn will offer covered bonds for sale via auction held on Thursday 13 June at 15:00. An inflation-linked series, LBANK CBI 30, will be offered for sale. In connection with the auction, a covered bond exchange offering will take place, where holders of the inflation-linked series LBANK CBI 24 can sell the covered bonds in the series against covered bonds bought in the above-mentioned auction. The clean price of the bonds is predefined at 99,594. Expected settlement date is 20 June 2024. Covered bonds issued by Landsbankinn are rated A+ with stable outlook by S&P Global Ratings. Landsbankinn Capital Markets will manage the auction. For further information, please call +354 410 7330 or email verdbrefamidlun@landsbankinn.is.
Relay42 unlocks customer intelligence with a new insights and reporting module, powered by Amazon QuickSight11.6.2024 11:00:00 CEST | Press release
AMSTERDAM, June 11, 2024 (GLOBE NEWSWIRE) -- Relay42, a leading European Customer Data Platform (CDP), is leveraging Amazon QuickSight to power its new real-time customer intelligence, reporting, and dashboard module. Harnessing the breadth and quality of customer data, the new Insights module empowers marketing teams to dive deep into customer behaviors and gain invaluable insights into the performance of their marketing programs across all online, offline, paid, and owned marketing channels. Preview of the Relay42 Insights module, in pre-beta version Key capabilities of the Relay42 Insights module include: Deep insights into customer behaviors: With the Relay42 Insights module, marketers can ask unlimited questions about their data and gain a deeper understanding of how to serve their customers more effectively. Simplicity with AI-powered querying: Marketers can use artificial intelligence to query their data using natural language search, reducing the reliance on data scientists. Us
Metasphere Labs Announces X Spaces Event on the Topic of Green Bitcoin Mining and Sound Money for Sustainability11.6.2024 10:30:00 CEST | Press release
VANCOUVER, British Columbia, June 11, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere Labs" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is thrilled to announce an engaging Twitter Spaces event on Green Bitcoin mining, energy markets, and sustainability on July 3, 2024 at 2 p.m. ET. Follow us on X at MetasphereLabs for updates and to join the event. What We'll Discuss Bitcoin Mining Basics: Understand the fundamentals of Bitcoin mining.Energy Market Dynamics: Explore how Bitcoin mining interacts with energy markets.Sustainable Innovations: Learn about our efforts to promote sustainability in Bitcoin mining.Sound Money: Discover how tamper-proof currency can enhance stability.Efficient Payment Rails: See how fast, neutral payment systems support humanitarian projects.Carbon Footprint: Compare Bitcoin's environmental impact with traditional banking. "We're excited to host this event and dive into the critical topics of Bitcoin